Latest News
An Interview With Josh Disbrow, CEO of Aytu BioPharma
Phase 3 Results Show Safety and Tolerability of LIQ861 for PAH
Sotatercept Analog Reverses Inflammation in PAH
Study Identifies Effective Clinical Dose of Sildenafil for Newborns With PAH
STAT3 Inhibition Shows Promise for Preventing Muscle Wasting in PAH
Wide-Field SHG Microscopy Could Help Visualize Fibrotic Pathogenesis in PAH
Postsystolic Strain Patterns Assess Right Ventricular Compromise in IPAH
Conduction Disease Associated With High Mortality in PAH
Experimental Design of Phase 2b PAH Clinical Trial Published
Latest Clinical Trials
Features
Aytu BioPharma’s Healight Device Could Help Treat Rare Pulmonary Diseases
Aytu BioPharma has developed an endotracheal respiratory catheter which its CEO says has “tremendous potential” in IPF, PAH, and other respiratory diseases.
Israel Emerges as Global Powerhouse in Rare Disease Research
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
Could a Mobile App Boost the Utility of the Six-Minute Walk Test in PAH?
Two important uses of the 6-MWT are pretreatment and posttreatment comparisons and predicting morbidity and mortality in patients with pulmonary hypertension
The Prognosis for Patients With PAH Is Improving, but Early Detection Is Key
New York City’s Noah Greenspan, DPT, says early detection is key for pulmonary arterial hypertension (PAH), but the prognosis for PAH is improving.
NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards
Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses.
PAH Patient Perspectives
Should I Have Another Catheterization for My Pulmonary Arterial Hypertension?
I live with pulmonary arterial hypertension (PAH), a progressive rare disease that is treated by addressing the symptoms only and not the disease.
For This PAH Patient, Curves and Detours on the Road to Diagnosis
In the summer of 2015, I had started to feel early symptoms of what would become a diagnosis of pulmonary arterial hypertension (PAH).
PAH Clinical Insights
Prescribing Physical Exercise to Improve Outcomes in PAH
Clinical researchers are emphasizing the value of exercise in alleviating the symptoms of some diseases, including pulmonary arterial hypertension (PAH).
The Role of Carbon Monoxide in Regulating Lung Function and Treating PAH
Members of the general public generally recognize carbon monoxide (CO) as a toxic gas that can be lethal if a person is exposed to large quantities of it over a short period of time. CO poisoning is insidious because the gas itself is colorless, tasteless, and odorless, making it harder to detect. In a study…
Beta-Blockers in Pulmonary Arterial Hypertension: Friend or Foe?
Beta-blockers may have different effects in the early stages of pulmonary arterial hypertension than in later stages of the disease.
Pediatric Considerations When Treating Pulmonary Arterial Hypertension
We discuss the challenges of treating pediatric patients with PAH, especially the scarcity of clinical data specific to children.
Managing Hemoptysis in PAH Associated With Congenital Heart Disease
The progressive changes associated with PAH predispose patients to developing hemoptysis, especially when congenital heart disease is also present.
The Complex Challenge of Treating IPF With Comorbid Pulmonary Hypertension
We explore the vast medical challenge of treating the combination of idiopathic pulmonary fibrosis and pulmonary hypertension successfully.
Rare Care Podcast
Noah Greenspan, DPT, founder of New York City’s Pulmonary Wellness & Rehabilitation Center, runs the nonprofit Pulmonary Wellness Foundation. In this interview, he talks about diagnosing and treating pulmonary arterial hypertension.
PAH Meeting Coverage
- Loading...
Loading...
Loading... 
Loading...